Analytical Data
-
Gene name
CCL3L1
- Application
-
Alternative Names
CCL3-L1; LD78; SCYA3L; SCYA3L1; MIP1AP; MIP1-Alpha-P; Small Inducible Cytokine A3-Like 1; Macrophage Inflammatory Protein 1-Alpha-P; Tonsillar Lymphocyte LD78 Beta
-
Species
Human
-
Source
E. coli
-
Tag
N- His & GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P16619
-
Expression Region
Met1~Ala93
-
Molecular Weight
40.16kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL3L1, also known as macrophage inflammatory protein-1-like protein 1, is a member of the CC chemokine family and plays a crucial role in immune responses. Its primary function involves recruiting immune cells, particularly T cells and monocytes, to sites of inflammation or infection. Research has shown that variations in CCL3L1 gene copy number are associated with susceptibility to various diseases, including autoimmune disorders, infectious diseases, and certain cancers. Notably, lower gene copy numbers have been linked to an increased risk of HIV infection and progression to AIDS, highlighting its potential as a biomarker for disease vulnerability. Furthermore, CCL3L1 is involved in various physiological processes, including angiogenesis and tissue remodeling, thus suggesting its relevance in both innate and adaptive immunity. Recent studies have explored the development of recombinant CCL3L1 proteins to investigate their therapeutic potential and elucidate their role in modulating immune responses. By producing and studying recombinant CCL3L1, researchers aim to better understand its mechanisms of action and explore its applications in immunotherapy and vaccine development. Overall, the study of CCL3L1 and its recombinant forms holds promise for advancing knowledge in immunology and developing novel therapeutic strategies for various conditions where immune modulation is beneficial.
